Flank Pain as a First Symptom of a Diffuse Midline Glioma
Diffuse midline gliomas are a new entity in the WHO Classification of Tumors of the Central Nervous System, corresponding to grade 4 gliomas. The diagnostic pathognomonic feature is the presence of a H3K27M mutation. Although mainly seen in children, cases in adults have also been reported. The symptoms are highly variable and usually dependent on the location and extent of spinal cord compression.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Flank Pain as a First Symptom of a Diffuse Midline Glioma ; volume:15 ; number:1 ; year:2023 ; pages:1-5 ; extent:5
Case reports in neurology ; 15, Heft 1 (2023), 1-5 (gesamt 5)
- Creator
-
Bassa, Burc
Battmann, Achim
Craemer, Eva Maria
Meyding-Lamadé, Uta
- DOI
-
10.1159/000528311
- URN
-
urn:nbn:de:101:1-2024010323425954174027
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bassa, Burc
- Battmann, Achim
- Craemer, Eva Maria
- Meyding-Lamadé, Uta
Other Objects (12)
Prognostic factors analysis of diffuse midline glioma
Correction to: Prognostic factors analysis of diffuse midline glioma
Specific Combination Therapy for H3K27M Pediatric Diffuse Midline Glioma
A H3K27M-targeted vaccine in adults with diffuse midline glioma
MRI comparative study of diffuse midline glioma, H3 K27-altered and glioma in the midline without H3 K27-altered
Infusion-related side-effects during convection enhanced delivery for brainstem-diffuse midline glioma/diffuse intrinsic pontine glioma
Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma
A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis
Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma
Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma
A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma
Prognostic factors analysis of diffuse midline glioma
Correction to: Prognostic factors analysis of diffuse midline glioma
Specific Combination Therapy for H3K27M Pediatric Diffuse Midline Glioma
A H3K27M-targeted vaccine in adults with diffuse midline glioma
MRI comparative study of diffuse midline glioma, H3 K27-altered and glioma in the midline without H3 K27-altered
Infusion-related side-effects during convection enhanced delivery for brainstem-diffuse midline glioma/diffuse intrinsic pontine glioma
Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma
A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis
Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma
Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma
A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma
Prognostic factors analysis of diffuse midline glioma
Correction to: Prognostic factors analysis of diffuse midline glioma
Specific Combination Therapy for H3K27M Pediatric Diffuse Midline Glioma
A H3K27M-targeted vaccine in adults with diffuse midline glioma
MRI comparative study of diffuse midline glioma, H3 K27-altered and glioma in the midline without H3 K27-altered
Infusion-related side-effects during convection enhanced delivery for brainstem-diffuse midline glioma/diffuse intrinsic pontine glioma
Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma
A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis
Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma
Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma